Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 1 14Phase 1/2 12Phase 3 6Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Completed 16Active not recruiting 13Recruiting 6Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 4Other hematologic neoplasm 1Breast 1

Conditions

Ovarian Neoplasms 3Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × olaparib × Clear all
NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting
3,500 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06915025 2026-06-02

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NRG Oncology

Phase 3 Recruiting
880 enrolled
Gynecologic

Ovarian Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
554 enrolled
Gynecologic

Endometrial Neoplasms

NCT05255471 2023-03-24

MITO 35B

National Cancer Institute, Naples

Phase 3 Recruiting
200 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡